MVA-BN Brachyury TRICOM vaccine

Drug Profile

MVA-BN Brachyury TRICOM vaccine

Alternative Names: Brachyury/TRICOM; MVA-brachyury-TRICOM

Latest Information Update: 13 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Bavarian Nordic; National Cancer Institute (USA)
  • Class Cancer vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase I Solid tumours

Most Recent Events

  • 08 Nov 2017 Bavarian Nordic plans a phase I fowlpox booster study of MVA-BN Brachyury TRICOM vaccine by the end of 2017
  • 08 Nov 2017 Bavarian Nordic plans a phase II study in Chordoma in the second half of 2018
  • 18 Apr 2017 Bavarian Nordic in-licenses EB66® cell-line technology from Valneva
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top